Prognostic value of CRM1 in pancreas cancer.
OBJECTIVE
Pancreatic cancer is a highly aggressive malignant tumour with poor prognosis. The median survival is only 6 months. This study investigated the prognostic value of nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) expression in pancreas cancer.


METHODS
CRM1 expression was detected, by Western blot, in pancreatic tissue from 69 cancer patients and 10 normal subjects.


RESULTS
CRM1 showed increased expression in pancreatic cancer tissue (P = 0.007). The high expression of CRM1 was associated with increased serum levels of CEA (P = 0.002) and CA19-9 (P = 0.005). There was an association between CRM1 expression and tumour size (P = 0.01), lymphadenopathy (P = 0.004) and liver metastasis (P = 0.003). High CRM1 expression was not correlated with the other clinicopathological parameters. High CRM1 expression was a prognostic indicator for progression-free survival (PFS) (P = 0.006) as well as overall survival (OS) (P = 0.001). Expression of CRM1 was an independent prognostic parameter for poorer PFS and OS (95% CI, 1.27-5.39).


CONCLUSIONS
CRM1 expression demonstrated prognostic value in pancreatic cancer. Prospective studies are required to determine the prognostic role of high expression of CRM1 in pancreatic cancer.
Huang
Wei-yi
WY
Department of Oncology, Affiliated People's 1st Hospital, Shanghai Jiaotong University, Shanghai, PR China 200085.
Yue
Lu
L
Qiu
Wen-shen
WS
Wang
Li-Wei
LW
Zhou
Xiao-han
XH
Sun
Yuan-jue
YJ
D000328:Adult; D000368:Aged; D015153:Blotting, Western; D005260:Female; D006801:Humans; D028884:Karyopherins / Q000097:blood* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood* / Q000235:genetics; D000097606:Exportin 1 Protein
D028884:Karyopherins; D018160:Receptors, Cytoplasmic and Nuclear; D000097606:Exportin 1 Protein